Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash ...

Recursion 2026年第一季度每股收益（EPS）为-0.22美元，超出市场预期的-0.26美元；但营收表现不佳，录得647万美元，远低于市场预期的1628万美元，差距高达60.26%。 受喜忧参半的业绩和营收大幅不及预期的影响，公司股价在盘前交易中下跌1.84%，报3.20美元。 公司将现金运营支出同比削减了30%；并维持6.65亿美元的现金头寸，这将公司财务跑道延长至2028年初。 公司 ...

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...

Investing.com -- 杰富瑞（Jefferies）周二发布了一份研究报告，通过分析过去90天内42份专家访谈记录，深入... 智通财经APP获悉，招银国际发布研报称，当前AI制药的价值主要体现在早期研发效率的提升上，核心壁垒正从算法转向数据资产。该行认为 ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence (AI) ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

Hi, everyone. Let's get started. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Priyanka Grover, and I'm part of the JPMorgan Biotech team. Today, our next presenting company is ...

Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...

One way to think about artificial intelligence, in its modern deep learning form, is as a jigsaw puzzle. You have a picture on the box, and you begin to organize your pieces. "I usually start by ...